Skip to main content
SpringerLink
Log in

Antiangiogene Therapie am vorderen Augenabschnitt

Inhibition of angiogenesis in the anterior chamber of the eye

  • Das therapeutische Prinzip
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

Zusammenfassung

Hintergrund

In den letzten Jahren wurden gewaltige Fortschritte im Verständnis neovaskulärer Erkrankungen des Auges gemacht. Neue antiangiogene Medikamente habe in die Therapie der AMD und der diabetischen Retinopathie Einzug gehalten. Ziel dieser Arbeit ist es, aktuelle und zukünftige Möglichkeiten der lokalen antiangiogenen Therapie an Hornhaut, Bindehaut und Vorderkammer aufzuzeigen.

Methoden

Literaturübersicht aus PUBMED und eigene klinische und experimentelle Daten.

Ergebnisse

Es gibt erste Erfolg versprechende Erfahrungen mit topischen Inhibitoren der Angiogenese (v. a. Bevacizumab) an der Hornhaut und Bindehaut sowie beim intrakameralen Einsatz.

Schlussfolgerungen

Neue topische antiangiogene Therapieoptionen zum lokalen Einsatz an Hornhaut und Bindehaut sind derzeit bereits off-label verfügbar und werden die Therapie angiogener Erkrankungen am vorderen Augenabschnitt deutlich verbessern.

Abstract

Background

Recent years have seen tremendous progress in our understanding of the mechanisms of neovascular diseases of the eye. Antiangiogenic treatment options are now widely used in the management of age-related maculopathy (AMD) and diabetic retinopathy. The aim of this article is to highlight some novel methods of local antiangiogenic treatment of the cornea and conjunctiva and in the anterior chamber of the eye.

Methods

The study took the form of a literature review (PUBMED) and a review of the authors’ own data.

Results

Initial experience with novel inhibitors of angiogenesis, especially bevacizumab, used locally on cornea and conjunctiva is promising. Intracameral injections of VEGF inhibitors can be used to ameliorate neovascular glaucoma.

Conclusion

Novel antiangiogenic drugs are available for topical use in the anterior segment of the eye (as off-label use) and will improve the management of neovascular diseases affecting cornea and conjunctiva and in the anterior chamber of the eye.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6
Abb. 7
Abb. 8
Abb. 9

Literatur

  1. Bock F, Onderka J, Dietrich T et al. (2007) Bevacizumab is a potent inhibitor of inflammatory angiogenesis and lymphangiogenesis in the cornea. Invest Ophthalmol Vis Sci (im Druck)

  2. Chen L, Hamrah P, Cursiefen C et al. (2004) Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3) mediates dendritic cell migration to lymph nodes and induction of immunity to corneal transplants. Nature Medicine 10: 813–815

    Article  PubMed  Google Scholar 

  3. Cursiefen C (2007) Immune privilege and angiogenic privilege of the cornea. Chem Immunol Allergy. 92: 50–57

    Google Scholar 

  4. Cursiefen C, Schlötzer-Schrehardt U, Küchle M et al. (2002) Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and Podoplanin. Invest Ophthalmol Vis Sci 43: 2127–2135

    PubMed  Google Scholar 

  5. Cursiefen C, Chen L, Dana MR et al. (2003) Corneal lymphangiogenesis: Evidence, mechanisms and implications for transplant immunology. Cornea 22: 273–2781

    Article  PubMed  Google Scholar 

  6. Cursiefen C, Seitz B, Dana MR et al. (2003) Angiogenese und Lymphangiogenese in der Hornhaut: Pathogenese, Klinik und Therapieoptionen. Ophthalmologe 100: 292–299

    Article  PubMed  Google Scholar 

  7. Cursiefen C, Rummelt C, Neuhuber W et al. (2006) Absence of blood and lymphatic vessels in the developing human cornea. Cornea 25: 722–726

    Article  PubMed  Google Scholar 

  8. Cursiefen C, Maruyama K, Liu Y et al. (2004) Inhibition of hem- and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 45: 2666–2673

    Article  PubMed  Google Scholar 

  9. Cursiefen C, Chen L, Saint-Geniez M et al. (2006) Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci USA103: 11405–11410

    Article  Google Scholar 

  10. Cursiefen C, Seitz B, Kruse F (2005) Hornhauttransplantation: Glänzende Bilanz und viele Perspektiven. Deutsches Ärztebl 102: A-3078

    Google Scholar 

  11. Cursiefen C, Chen L, Borges L, Jackson D, D’Amore PA, Dana MR, Wiegand SJ, Streilein JW. Via bone marrow-derived macrophages, VEGF A mediates lymph- and hemangiogenesis in inflammatory neovascularization. J Clin Investigation 113: 1040–1050

  12. Cursiefen C, Ikeda S, Nishina PM et al. (2005) Spontaneous corneal hem- and lymphangiogenesis in mice with destrin-mutation depend on VEGFR3-signaling. Am J Pathol 166: 1367–1377

    PubMed  Google Scholar 

  13. Cursiefen C, Masli S, Ng TF et al. (2004) Roles of thrombospondin 1 and 2 in regulating spontaneous and induced angiogenesis in the cornea and iris. Invest Ophthalmol Vis Sci 45: 1117–1124

    Article  PubMed  Google Scholar 

  14. Cursiefen C, Maruyama M, Jackson DG et al. (2006) Time-course of angiogenesis and lymphangiogenesis after brief corneal inflammation. Cornea 25: 443–447

    Article  PubMed  Google Scholar 

  15. Cursiefen C, Martus P, Nguyen NX et al. (2002) Corneal neovascularization after nonmechanical versus mechanical corneal trephination for non-high-risk keratoplasty. Cornea 21: 648–652

    Article  PubMed  Google Scholar 

  16. Cursiefen C, Wenkel H, Martus P et al. (2001) Peripheral corneal neovascularization after non-high risk-keratoplasty: influence of short- versus longtime topical steroids. Graefe’s Arch Clin Exp Ophthalmol 239: 514–521.

    Google Scholar 

  17. Cursiefen C, Wenkel H, Langenbucher A et al. (2001) Standardisiertes Beurteilungsschema zur semiquantitativen Analyse der kornealen Neovaskularisation mittels projizierter Hornhautphotographien. Klin Monatsbl Augenheilkd 218: 484–491

    Article  PubMed  Google Scholar 

  18. Cursiefen C, Rummelt C, Küchle M (2000) Immunohistochemical localization of VEGF, TGFa and TGFb1 in human corneas with neovascularization. Cornea 19: 526–533

    Article  PubMed  Google Scholar 

  19. Cursiefen C, Rummelt C, Küchle M et al. (2003) Pericyte recruitment in human corneal angiogenesis. Br J Ophthalmol 87: 101–106

    Article  PubMed  Google Scholar 

  20. Geitzenauer W, Michels S, Prager F et al. (2006) Early effects of systemic and intravitreal bevacizumab (avastin) therapy for neovascular age-related macular degeneration. Klin Monatsbl Augenheilkd 223: 822–827

    Article  PubMed  Google Scholar 

  21. Grisanti S, Biester S, Peters S et al. (2006) Tuebingen Bevacizumab Study Group. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 142: 158–160

    Article  PubMed  Google Scholar 

  22. Iliev ME, Domig D, Wolf-Schnurrbursch U (2006) Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 142: 1054–1056

    Article  PubMed  Google Scholar 

  23. Jonas JB, Spandau UH, Schlichtenbrede F (2007) Intravitreal Bevacizumab for filtering surgery. Ophthalmic Res 39: 121–122

    Article  PubMed  Google Scholar 

  24. Kahook MY, Schumann JS, Noecker RJ (2006) Needle bleb revision of encapsulated filtering bleb with bevacizumab. Ophthalmic Surg Lasers Imaging 37: 148–150

    PubMed  Google Scholar 

  25. Klink T, Guthoff R, Grehn F (2006) Postoperative care after glaucoma filtration surgery. Ophthalmologe 103: 815–823

    Article  PubMed  Google Scholar 

  26. Kria L, Ohira A, Amemiya T (1998) TNP-470 (a fungus-derived inhibitor of angiogenesis) reduces proliferation of cultured fibroblasts isolated from primary pterygia: a possible drug therapy for pterygia. Curr Eye Res 17: 986–993

    Article  PubMed  Google Scholar 

  27. Kuhlmann A, Amann K, Schlötzer-Schrehardt U (2005) Endothelin-1 and Eta/Etb-receptor expression in normal & vascularized human cornea. Cornea 24: 837–844

    Article  PubMed  Google Scholar 

  28. Manzano R et al. (2007) Inhibition of experimental corneal neovascularization by Bevacizumab (AVASTIN). Br J Ophthalmol (in press)

  29. Maruyama K, Li M, Cursiefen C et al. (2005) Inflammatory lymphangiogenesis arises from CD11b+ cells. J Clin Invest 115: 2363–2372

    Article  PubMed  Google Scholar 

  30. Nguyen N, Seitz B, Langenbucher A et al. (2004) Clinical aspects and treatment of immune reactions following penetrating normal-risk keratoplasty. Klin Monatsbl Augenheilkd 221: 467–472

    Article  PubMed  Google Scholar 

  31. Pillai CT, Dua HS, Hossain P (2000) Fine needle diathermy occlusion of corneal vessels. Invest Ophthalmol Vis Sci 41: 2148–2153

    PubMed  Google Scholar 

  32. Shaunak S, Thomas S, Gianasi E et al. (2004) Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat Biotechnol 22: 977–984

    Article  PubMed  Google Scholar 

  33. Shojaei F, Ferrara N (2007) Antiangiogenesis to treat cancer and intraocular neovascular disorders. Lab Invest (Epub ahead of print)

  34. Vinh L, Nguyen N, Martus P (2006) Surgery-related factors influencing corneal neovascularization after low-risk keratoplasty. Am J Ophthalmol 141: 260–266

    Article  PubMed  Google Scholar 

  35. Wong J, Wang N, Miller JW (1994) Modulation of human fibroblast activity by selected angiogenesis inhibitors. Exp Eye Res 58: 439–451

    Article  PubMed  Google Scholar 

  36. Yeoh J, Sims J, Guymer RH (2006) A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother 7: 2355–2368

    Article  PubMed  Google Scholar 

Download references

Danksagung

Wir danken Frau Straub, Universitätsklinikum Erlangen-Nürnberg, für die Hilfe bei der Herstellung von Avastin®-Augentropfen.

Interessenkonflikt

Erlangen ist Studienort der Multizenterstudie zu Erprobung von GS-101-Augentropfen.

Trotz des möglichen Interessenkonflikts ist der Beitrag unabhängig und produktneutral.

Author information

Authors and Affiliations

  1. Augenklinik mit Poliklinik, Friedrich-Alexander-Universität Erlangen Nürnberg, Schwabachanlage 6, 91054, Erlangen, Deutschland

    F. Bock, Y. König, T. Dietrich, P. Zimmermann &  C. Cursiefen

  2. Klinikumsapotheke, Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Deutschland

    M. Baier

Authors
  1. F. Bock
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y. König
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Dietrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Zimmermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Baier
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Cursiefen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Cursiefen.

Additional information

Mit Unterstützung durch das Interdisziplinäre Zentrum für Klinische Forschung (IZKF) Erlangen (A9, A20), ELAN Fonds Universität Erlangen, DFG (Cu 47/2–1).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bock, F., König, Y., Dietrich, T. et al. Antiangiogene Therapie am vorderen Augenabschnitt. Ophthalmologe 104, 336–344 (2007). https://doi.org/10.1007/s00347-007-1512-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-007-1512-2

Schlüsselwörter

Keywords

Search

Navigation